|
Time
for a makeover
Organised players are slowly making inroads into the highly
fragmented Indian pharma retail industry, thereby changing
the dynamics of the segment. Nandini Patwardhan takes a look
at the new emerging trend in pharmaceuticals industry.
Upfront
Mastering
the art
Sonal Shukla reports the Annual Contract Research and Clinical
Trials conference
Meeting
world class standards
India's World Class Laboratory Leadership Conference was organised
by Infor-media on June 22 and 23, 2006, in Mumbai.
Upcoming
Events
Glenmark
extends generic base
Glenmark Pharmaceutica UK and Merck Generics Group have entered
into an agreement for the joint development, filing and marketing
of eight generic dermatological products for Europe, which
have a current annual sales value of around $225 million in
the region.
Panacea
Biotec strikes deal with Indonesian company
Panacea Biotec announced their agreement with PT. Bio Farma,
Indonesia, to manufacture and market their measles vaccine.
Blackstone
to invest $50 million in Emcure
Emcure Pharmaceuticals and The Blackstone Group, announced
that Emcure's Board of Directors has approved an agreement
as part of which, The Blackstone Group and its affiliates
would invest $50 million in the company.
'Chromatography
is expensive but important'
Waters' solutions are widely used by researchers to push the
boundaries of analytical science. K V Venugopalan, President
of Waters India, talks to Sonal Shukla on the company's operations
and future plans.
An
insight into pharma M&A
The pharma vertical is known for their intense M&A activity.
Pricewater-houseCoopers Corporate Finance has published its
annual review of pharma M&A called Insights. The report
highlights the deals and developments seen in this dynamic
sector.
The
Para IV charm continues
Indian generic companies challenge blockbuster drugs from
MNCs via Para IV filing of their ANDA in the US and Europe.
Even though Para IV challengers are facing stiff competition,
the trend is here to stay, finds Sapna Dogra.
|
